A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

Prior treatment

• Prior treatment with idelalisib, other selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors, or a pan PI3K inhibitor.
• Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of first dose of study treatment.

Other illness

• History of central nervous system lymphoma (either primary or metastatic).
• Active graft-versus-host disease.
• Liver disease: Participants positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for hepatitis B virus-deoxyribonucleic acid (HBV-DNA). Participants positive for anti-hepatitis C virus (HCV) antibody will be eligible if they are negative for HCV-ribonucleic acid (RNA).

• Men and women, aged 18 years or older.
• Documented failure to achieve at least partial response (PR) with, or documented disease progression after, the most recent treatment regimen.
• Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy.
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.